News
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...
10h
Clinical Trials Arena on MSNResponse’s post-GLP-1RA drug reduces weight rebound in Phase II
Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...
GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.
Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.
Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...
Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...
For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...
1d
HealthDay on MSNGLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...
Glucagon-like peptide-1 (GLP-1) is a hormone that is naturally produced by the body and which helps regulate blood sugar ...
Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results